Trimetazidine as cardioplegia addictive without pre-treatment does not improve myocardial protection: study in a swine working heart model.
OBJECTIVE
The aim of this study is to verify in an isolated working heart swine model if the acute administration of trimetazidine to cardioplegia, without pre-treatment improves heart performance.


METHODS
Eighteen pairs of swine were used in this working heart model, divided into three groups (n = 6) that underwent regional and global ischemia. Each group was selected to a different treatment: St. Thomas cardioplegia (ST), St. Thomas enriched with trimetazidine (TMZ) and control group (Co). Data was collected during reperfusion period at 30, 60 and 90 minutes. Hemodynamic parameters such as elastance contractility index (Emax), preload recruitable stroke work relationship (PRSW) and heart "stiffness" (EDPVR) were measured. Other data included coronary flow, lactate, oxygen and glucose consumption. Results were statistically analyzed.


RESULTS
All contractility data were not significantly different among three groups. Lactate became constantly higher according to time uniformly in all three groups. Coronary flow, glucose consumption and oxygen consumption presented large variations during time periods but according to treatments showed no statistical differences in all three groups. Left ventricle final weight was significantly lower in trimetazidine group compared to both other groups.


CONCLUSIONS
Administration of trimetazidine enhanced cardioplegia, without pre-treatment, showed no hemodynamic or metabolic improvement in swine isolated working heart model.
Silveira Filho
Lindemberg da Mota
Lda M
Faculdade de Ciências Médicas, Universidade Estadual de Campinas. lindembergms@uol.com.br
Petrucci
Orlando
O
Carmo
Marcio Roberto de
MR
Oliveira
Pedro Paulo Martins de
PP
Vilarinho
Karlos Alexandre Sousa
KA
Vieira
Reinaldo Wilson
RW
Braile
Domingo Marcolino
DM
D000704:Analysis of Variance; D000818:Animals; D001639:Bicarbonates / Q000494:pharmacology; D002122:Calcium Chloride / Q000494:pharmacology; D002314:Cardioplegic Solutions / Q000494:pharmacology*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D019344:Lactic Acid / Q000378:metabolism; D008274:Magnesium / Q000494:pharmacology; D023421:Models, Animal; D008955:Models, Cardiovascular; D009200:Myocardial Contraction / Q000187:drug effects* / Q000502:physiology; D017202:Myocardial Ischemia / Q000378:metabolism*; D015425:Myocardial Reperfusion; D010101:Oxygen Consumption / Q000187:drug effects / Q000502:physiology; D010477:Perfusion / Q000379:methods; D011189:Potassium Chloride / Q000494:pharmacology; D012965:Sodium Chloride / Q000494:pharmacology; D013552:Swine; D013997:Time Factors; D014292:Trimetazidine / Q000494:pharmacology*
D001639:Bicarbonates; D002314:Cardioplegic Solutions; C041711:St. Thomas' Hospital cardioplegic solution; D019344:Lactic Acid; D012965:Sodium Chloride; D011189:Potassium Chloride; D008274:Magnesium; D002122:Calcium Chloride; D014292:Trimetazidine